Company Filing History:
Years Active: 2018
Title: Innovations of Lingyun Li in Antibody Development
Introduction
Lingyun Li is a notable inventor based in Shanghai, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of antibodies. His work focuses on innovative solutions that address critical health challenges.
Latest Patents
Lingyun Li holds a patent for an anti-human RANKL antibody, which includes a humanized antibody and a pharmaceutical composition. This invention provides a specific bonding capability with an amino acid sequence of SEQ ID NO.1. The heavy chain of the anti-human RANKL antibody features a variable region from one of the amino acid sequences of SEQ ID NO.2-9. Additionally, the light chain includes a variable region from SEQ ID NO.10-17. The humanized antibody is designed to bond specifically with human RANKL, utilizing variable regions selected from various amino acid sequences.
Career Highlights
Lingyun Li is currently employed at Genor Biopharma Co., Ltd. His role at the company allows him to engage in cutting-edge research and development in the biopharmaceutical sector. His innovative work has positioned him as a key figure in the advancement of therapeutic antibodies.
Collaborations
Lingyun Li collaborates with talented professionals in his field, including coworkers such as Qing Zhou and Xiao Feng. These collaborations enhance the research and development process, fostering an environment of innovation and creativity.
Conclusion
Lingyun Li's contributions to the field of antibody development exemplify the impact of innovative research in biopharmaceuticals. His patent for the anti-human RANKL antibody showcases his commitment to advancing medical science.